Evolution of hepatitis C virus in liver allografts

Liver Transplantation

Volumn 15, Issue SUPPL. 2, 2009, Pages

  Demetris, Anthony J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; VIRUS RNA;

ALLOGRAFT; ARTICLE; AUTOIMMUNE HEPATITIS; CD4+ T LYMPHOCYTE; CHOLESTATIC HEPATITIS; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT; NEEDLE BIOPSY; PRIORITY JOURNAL; RECURRENT INFECTION; REPERFUSION INJURY; VIRUS PATHOGENESIS; VIRUS REPLICATION; ALLOTRANSPLANTATION; GENETICS; ISOLATION AND PURIFICATION; LIVER TRANSPLANTATION; MICROBIOLOGY; PATHOLOGY; RECURRENT DISEASE;

HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; RECURRENCE; RNA, VIRAL; TRANSPLANTATION, HOMOLOGOUS;

EID: 77449152522     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21890     Document Type: Article

References (56)

1. Gane EJ,. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (suppl 2): S36-S44.
2. Ramirez S, Perez-Del-Pulgar S, Forns X,. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 2008; 14 (suppl 2): S27-S35.
3. McCaughan GW, Shackel NA, Bertolino P, Bowen DG,. Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation 2009; 87: 1105-1111.
4. Mengshol JA, Golden-Mason L, Rosen HR,. Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 622-634. (Pubitemid 350055563)
5. McCaughan GW, Zekry A,. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40: 368-374. (Pubitemid 38230834)
6. Spengler U, Nattermann J,. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007; 112: 141-155. (Pubitemid 46253881)
7. Demetris AJ, Lunz JG III,. Early HCV-associated stellate cell activation in aggressive recurrent HCV: what can liver allografts teach about HCV pathogenesis? Liver Transpl 2005; 11: 1172-1176.
8. Burton JR Jr, Rosen HR,. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl 2006; 12: S38-S47. (Pubitemid 44742524)
9. Zekry A, Bishop GA, Bowen DG, Gleeson MM, Guney S, Painter DM, McCaughan GW,. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002; 8: 292-301. (Pubitemid 34257213)
10. Demetris AJ, Eghtesad B, Marcos A, Ruppert K, Nalesnik MA, Randhawa P, et al. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004; 28: 658-669. (Pubitemid 38579570)
11. Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007; 56: 237-242. (Pubitemid 46246212)
12. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S, Berenguer J,. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722.
13. Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44: 702-709.
14. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78: 966-971. (Pubitemid 39391856)
15. Eghtesad B, Fung JJ, Demetris AJ, Murase N, Ness R, Bass DC, et al. Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl 2005; 11: 1343-1352. (Pubitemid 43071583)
16. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
17. Tillmann HL, Manns MP, Rudolph KL,. Merging models of hepatitis C virus pathogenesis. Semin Liver Dis 2005; 25: 84-92. (Pubitemid 40322353)
18. Russo MW, Firpi RJ, Nelson DR, Schoonhoven R, Shrestha R, Fried MW,. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl 2005; 11: 1235-1241. (Pubitemid 41511938)
19. Gawrieh S, Papouchado BG, Burgart LJ, Kobayashi S, Charlton MR, Gores GJ,. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005; 11: 1207-1213. (Pubitemid 41511934)
20. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR,. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41: 809-818.
21. Lunz JG III, Tsuji H, Nozaki I, Murase N, Demetris AJ,. An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology 2005; 41: 1262-1271. (Pubitemid 40770278)
22. Berenguer M,. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-S18. (Pubitemid 35154038)
23. Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayon M, San Juan F, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003; 9: 1152-1158. (Pubitemid 37407983)
24. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790. (Pubitemid 43345017)
25. Berenguer M,. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl 2008; 14 (suppl 2): S45-S50.
26. Asanza CG, Garcia-Monzon C, Clemente G, Salcedo M, Garcia-Buey L, Garcia-Iglesias C, et al. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation. Hepatology 1997; 26: 755-763. (Pubitemid 27392370)
27. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, Corless CL,. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178-1182. (Pubitemid 28224334)
28. Rosen HR, Martin P,. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66: 1612-1616. (Pubitemid 29034979)
29. Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J,. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992; 16: 865-876.
30. Fiel M, Agarwal K, Stanca C, Elhaji N, Kontorinis N, Thung S, Schiano T,. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with HCV. Liver Transpl 2008; 14: 750-755. (Pubitemid 351895516)
31. Khettry U, Huang WY, Simpson MA, Pomfret EA, Pomposelli JJ, Lewis WD, et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 2007; 38: 443-452. (Pubitemid 46227528)
32. Demetris AJ, Sebagh M,. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl 2008; 14: 750-755. (Pubitemid 351895504)
33. Czaja AJ, Carpenter HA,. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997; 26: 459-466. (Pubitemid 27328326)
34. Czaja AJ, Carpenter HA,. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-1832.
35. Dai YD, Carayanniotis G, Sercarz E,. Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol 2005; 2: 169-175.
36. Vanderlugt CL, Miller SD,. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
37. Kessel A, Toubi E,. Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism. Curr Med Chem 2007; 14: 547-554. (Pubitemid 46477727)
38. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938. (Pubitemid 29514229)
39. Schiano TD, Te HS, Thomas RM, Hussain H, Bond K, Black M,. Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome. Am J Gastroenterol 2001; 96: 2984-2991. (Pubitemid 32959543)
40. Lunel F, Cacoub P,. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31 (suppl 1): 210-216. (Pubitemid 30002721)
41. Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, Czaja A, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489-501.
42. Demetris AJ,. Central venulitis in liver allografts: considerations of differential diagnosis. Hepatology 2001; 33: 1329-1330.
43. Dixon LR, Crawford JM,. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13: 219-226.
44. Tsamandas AC, Furukawa H, Abu-Elmagd K, Todo S, Demetris AJ, Lee RG,. Liver allograft pathology in liver/small bowel or multivisceral recipients. Mod Pathol 1996; 9: 767-773. (Pubitemid 26246585)
45. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
46. Lumbreras C, Colina F, Loinaz C, Domingo MJ, Fuertes A, Dominguez P, et al. Clinical, virological, and histologic evolution of hepatitis C virus infection in liver transplant recipients. Clin Infect Dis 1998; 26: 48-55. (Pubitemid 28068154)
47. Charco R, Vargas V, Allende H, Edo A, Balsells J, Murio E, et al. Is hepatitis C virus recurrence a risk factor for chronic liver allograft rejection? Transpl Int 1996; 9 (suppl 1): S195-S197. (Pubitemid 26385713)
48. Hoffmann RM, Gunther C, Diepolder HM, Zachoval R, Eissner HJ, Forst H, et al. Hepatitis C virus infection as a possible risk factor for ductopenic rejection (vanishing bile duct syndrome) after liver transplantation. Transpl Int 1995; 8: 353-359.
49. Jain A, Demetris AJ, Manez R, Tsamanadas AC, Van Thiel D, Rakela J, et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg 1998; 4: 197-203. (Pubitemid 28225645)
50. Dousset B, Conti F, Houssin D, Calmus Y,. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994; 330: 1160-1161. (Pubitemid 24118283)
51. Ontanon J, Muro M, Garcia-Alonso AM, Minguela A, Torio A, Bermejo J, et al. Effect of partial HLA class I match on acute rejection in viral pre-infected human liver allograft recipients. Transplantation 1998; 65: 1047-1053. (Pubitemid 28208422)
52. Pappo O, Ramos H, Starzl TE, Fung JJ, Demetris AJ,. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995; 19: 192-206.
53. Thung SN, Shim KS, Shieh YS, Schwartz M, Theise N, Borcich A, et al. Hepatitis C in liver allografts. Arch Pathol Lab Med 1993; 117: 145-149. (Pubitemid 23057614)
54. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638-645.
55. Dustin LB, Rice CM,. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25: 71-99.
56. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993; 17: 1127-1152. (Pubitemid 23187422)